Table 1 Baseline patient- and tumor characteristics for all patients.
Variable | Statistic | Total |
|---|---|---|
N | N | 685 |
Age (year) | Median | 54.0 |
Range | (22.0; 90.0) | |
Menopausal status | ||
Pre/perimenopause | n (%) | 274 (40.9%) |
Postmenopause | n (%) | 396 (59.1%) |
NA | n | 15 |
BMI (kg/m2) | Median | 24.7 |
Range | (14.2; 48.1) | |
T-stage | ||
T1 | n (%) | 288 (42.0%) |
T2 | 330 (48.2%) | |
T3 | 44 (6.4%) | |
T4 | 23 (3.4%) | |
NA | 0 | |
N-stage | ||
N0 | n (%) | 436 (63.8%) |
N1 | 180 (26.4%) | |
N2 | 41 (6.0%) | |
N3 | 26 (3.8%) | |
NA | 2 | |
N-stage | ||
Negative | n (%) | 436 (63.8%) |
Positive | 247 (36.2%) | |
NA | 2 | |
Grade | ||
1 | n (%) | 9 (1.3%) |
2 | 70 (10.2%) | |
3 | 606 (88.5%) | |
NA | 0 | |
DCIS | ||
No | n (%) | 255 (37.2%) |
Yes | 430 (62.8%) | |
NA | 0 | |
LVI | ||
No | n (%) | 428 (76.6%) |
Yes | 131 (23.4%) | |
NA | 126 | |
Histology | ||
IBC-NST | n (%) | 545 (79.6%) |
Mixed | 13 (1.9%) | |
Apocrine | 31 (4.5%) | |
BCmedullary | 40 (5.8%) | |
Metaplastic | 34 (5.0%) | |
Other* | 22 (3.2%) | |
NA | 0 | |
